99 related articles for article (PubMed ID: 10221814)
1. Antibody dependent cell-mediated cytotoxicity using hepatocellular carcinoma reactive monoclonal antibody.
Kuwata T; Haruta I; Hasegawa K; Yamauchi K; Hayashi N
J Gastroenterol Hepatol; 1998 Feb; 13(2):137-44. PubMed ID: 10221814
[TBL] [Abstract][Full Text] [Related]
2. Multiplicity of newly established monoclonal antibodies against hepatocellular carcinomas.
Ohzu K; Hasegawa K; Yamauchi K; Obata H
J Gastroenterol Hepatol; 1990; 5(6):601-7. PubMed ID: 1966596
[TBL] [Abstract][Full Text] [Related]
3. Human IgG3 monoclonal antibody directed to an unbranched repeating type 2 chain (Gal beta 1----4GlcNAc beta 1----3Gal beta 1----4GlcNAc beta 1----3Gal beta 1----R) which is highly expressed in colonic and hepatocellular carcinoma.
Miyake M; Kohno N; Nudelman ED; Hakomori S
Cancer Res; 1989 Oct; 49(20):5689-95. PubMed ID: 2551493
[TBL] [Abstract][Full Text] [Related]
4. A monoclonal antibody to the carbohydrate chain on human hepatocellular carcinoma-associated antigen which suppressed tumor growth in nude mice.
Fukuda Y; Imai K; Miura K; Matsui M; Nakanishi T; Nakazato H; Masukawa J; Higashide T; Hinoda Y; Noguchi T
Cancer Immunol Immunother; 1988; 27(1):26-32. PubMed ID: 2840199
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.
Kong J; Diao Z; Deng X; Zhong H; Yao W; Hu X
Oncol Rep; 2007 Jul; 18(1):279-85. PubMed ID: 17549380
[TBL] [Abstract][Full Text] [Related]
7. [Human monoclonal antibody constructed by lymphocytes from pancreatic cancer patients].
Tanaka H
Nihon Geka Gakkai Zasshi; 1989 Jan; 90(1):93-101. PubMed ID: 2539553
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
[TBL] [Abstract][Full Text] [Related]
9. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
Kinouchi T; Bander NH; Kotake T
J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
[TBL] [Abstract][Full Text] [Related]
10. A3--a novel colon and pancreatic cancer reactive antibody from a primate phage library selected using intact tumour cells.
Tordsson J; Lavasani S; Ohlsson L; Karlström P; Svedberg H; Abrahmsén L; Brodin T
Int J Cancer; 2000 Aug; 87(4):559-68. PubMed ID: 10918198
[TBL] [Abstract][Full Text] [Related]
11. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer.
Green SK; Karlsson MC; Ravetch JV; Kerbel RS
Cancer Res; 2002 Dec; 62(23):6891-900. PubMed ID: 12460904
[TBL] [Abstract][Full Text] [Related]
12. Induction of allogeneic tumour- and lymphokine-activated lymphocytes against hepatocellular carcinoma.
Yasumura S; Higuchi K; Hioki O; Okada K; Tsukishiro T; Tsuchida T; Miyagiwa M; Nambu S; Yasuyama T; Inoue K
J Gastroenterol Hepatol; 1992; 7(2):136-41. PubMed ID: 1315167
[TBL] [Abstract][Full Text] [Related]
13. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
14. A new murine monoclonal antibody against human hepatoma.
Stein R; Wang ZF; Sharkey RM; Klein KM; Goldenberg DM
Hybridoma; 1991 Apr; 10(2):255-67. PubMed ID: 1651901
[TBL] [Abstract][Full Text] [Related]
15. Self-reactive antibody expression by human carcinoma cells engineered with monoclonal antibody genes.
Primus FJ; Finch MD; Masci AM; Schlom J; Kashmiri SV
Cancer Res; 1993 Jul; 53(14):3355-61. PubMed ID: 8324746
[TBL] [Abstract][Full Text] [Related]
16. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Woodhouse CS; Morgan AC
Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
[TBL] [Abstract][Full Text] [Related]
17. Antigenic characterization of human hepatocellular carcinoma. Development of in vitro and in vivo immunoassays that use monoclonal antibodies.
Carlson RI; Ben-Porath E; Shouval D; Strauss W; Isselbacher KJ; Wands JR
J Clin Invest; 1985 Jul; 76(1):40-51. PubMed ID: 2991342
[TBL] [Abstract][Full Text] [Related]
18. Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.
Ma Z; He H; Sun F; Xu Y; Huang X; Ma Y; Zhao H; Wang Y; Wang M; Zhang J
J Cancer Res Clin Oncol; 2017 Oct; 143(10):1929-1940. PubMed ID: 28536738
[TBL] [Abstract][Full Text] [Related]
19. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel monoclonal antibody raised against human hepatocellular carcinoma.
Xie Y; Xie H
Hybridoma; 1998 Oct; 17(5):437-44. PubMed ID: 9873989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
